Literature DB >> 8938889

Epistaxis in hereditary haemorrhagic telangiectasia.

T Haitjema1, W Balder, F J Disch, C J Westermann.   

Abstract

Hereditary haemorrhagic telangiectasia (HHT) is characterized by easily bleeding telangiectases of the skin and mucosa. Epistaxis is the most common symptom of HHT. Larger arteriovenous malformations (AVM) occur in the lungs (in up to 33% of the patients), brain (in up to 11% of patients), and liver. These may cause severe complications which can be prevented by early therapy. To gain insight in the characteristics of epistaxis in HHT, 171 persons were investigated, who either had HHT or participated in a screening programme for relatives of HHT patients. Of these, 58 persons had HHT. Epistaxis without signs of HHT was present in 12 persons, whereas 10% of HHT patients did not have epistaxis. Seventeen HHT patients with epistaxis had visited an otorhinolaryngologist before, without a correct diagnosis of HHT being made. Telangiectases were most common on lips, tongue, the nasal septum, and the turbinates. In view of the prevalence of visceral AVM and the associated complications, HHT patients presenting to an otorhinolaryngologist should be encouraged to engage in a screening programme for these AVM.

Entities:  

Mesh:

Year:  1996        PMID: 8938889

Source DB:  PubMed          Journal:  Rhinology        ISSN: 0300-0729            Impact factor:   3.681


  9 in total

1.  Genotype-phenotype relationship in hereditary haemorrhagic telangiectasia.

Authors:  T G W Letteboer; J J Mager; R J Snijder; B P C Koeleman; D Lindhout; J K Ploos van Amstel; C J J Westermann
Journal:  J Med Genet       Date:  2005-09-09       Impact factor: 6.318

2.  Complications and mortality in hereditary hemorrhagic telangiectasia: A population-based study.

Authors:  James W Donaldson; Tricia M McKeever; Ian P Hall; Richard B Hubbard; Andrew W Fogarty
Journal:  Neurology       Date:  2015-04-10       Impact factor: 9.910

3.  ELLIPSE Study: a Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia.

Authors:  Sophie Dupuis-Girod; Alexis Ambrun; Evelyne Decullier; Géraldine Samson; Adeline Roux; Anne-Emmanuelle Fargeton; Catherine Rioufol; Verane Schwiertz; François Disant; François Chapuis; Yves Donazzolo; Gilles Paintaud; Patrick Edery; Frederic Faure
Journal:  MAbs       Date:  2014-01-30       Impact factor: 5.857

4.  Manifestations of hereditary hemorrhagic telangiectasia in children and adolescents.

Authors:  Benedikt J Folz; Barbara Zoll; Heiko Alfke; André Toussaint; Rolf F Maier; Jochen A Werner
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-06-24       Impact factor: 2.503

Review 5.  Hereditary hemorrhagic telangiectasia: an update on clinical manifestations and diagnostic measures.

Authors:  Haneen Sadick; Maliha Sadick; Karl Götte; Ramin Naim; Frank Riedel; Gregor Bran; Karl Hörmann
Journal:  Wien Klin Wochenschr       Date:  2006-03       Impact factor: 1.704

6.  Hereditary hemorrhagic telangiectasia: ENG and ALK-1 mutations in Dutch patients.

Authors:  T G W Letteboer; R A Zewald; E J Kamping; G de Haas; J J Mager; R J Snijder; D Lindhout; F A M Hennekam; C J J Westermann; J K Ploos van Amstel
Journal:  Hum Genet       Date:  2004-10-23       Impact factor: 4.132

7.  Visceral manifestations in hereditary haemorrhagic telangiectasia type 2.

Authors:  S A Abdalla; U W Geisthoff; D Bonneau; H Plauchu; J McDonald; S Kennedy; M E Faughnan; M Letarte
Journal:  J Med Genet       Date:  2003-07       Impact factor: 6.318

8.  Classification of endonasal HHT lesions using digital microscopy.

Authors:  F Haubner; A Schneider; H Schinke; M Bertlich; B G Weiss; M Canis; F Kashani
Journal:  Orphanet J Rare Dis       Date:  2021-04-17       Impact factor: 4.123

9.  Clinical features and mutations in the ENG, ACVRL1, and SMAD4 genes in Korean patients with hereditary hemorrhagic telangiectasia.

Authors:  Seung-Tae Lee; Jee-Ah Kim; Shin-Yi Jang; Duk-Kyung Kim; Young Soo Do; Gee Young Suh; Jong-Won Kim; Chang-Seok Ki
Journal:  J Korean Med Sci       Date:  2009-02-28       Impact factor: 2.153

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.